NCT01465529View on ClinicalTrials.gov

A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

November 30, 2013

Conditions
Cystic Fibrosis
Interventions
DRUG

OligoG CF-5/20

6% OligoG CF-5/20 in water

DRUG

Saline

0.9% NaCl in water

Trial Locations (3)

Dublin 9

Beaumont Hospital, Dublin

Unknown

University College Hospital Galway, Galway

L14 3PE

Liverpool Heart & Chest Hospital, Liverpool

Sponsors

Lead Sponsor

AlgiPharma AS
All Listed Sponsors
lead

AlgiPharma AS

INDUSTRY

NCT01465529 - A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis | Biotech Hunter | Biotech Hunter